Latest News and Press Releases

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...

Inclusion of Zai Lab shares in Shanghai-Hong Kong Stock Connect is effective today Zai Lab has been dual-primary listed on Nasdaq and the Hong Kong Stock Exchange, and its shares included in the...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., July 13, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...

–   First company to Convert from Secondary to Primary Listing Status in Hong Kong –   Our dual Primary Listing on the Nasdaq and Hong Kong Stock Exchange provides greater access for investors ...

-- Breakthrough Therapy Designations granted for ROS1-positive non-small cell lung cancer (NSCLC) patients pretreated with one prior line of ROS1 tyrosine kinase inhibitor (TKI) with or without prior...

Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% SHANGHAI and...

Presentation features a new subgroup analysis of the Phase 3 PRIME study exploring the efficacy of niraparib maintenance therapy for patients in China with advanced ovarian cancer based on their...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...